TechGuru,
I am more excited about DP's paper after the interview with Dr. Yo. As would be expected the paper is being improved by the review process and will now include "control patient" data for comparison to the patients who received Leronlimab. This seems particularly helpful since many of these extremely ill patients died.

Do you see the availability of this peer reviewed paper (assuming it is published in the next week or so), as helpful to the FDA in their decision process to approve Leronlimab? Would they use a peer reviewed paper as supporting data?

Thanks